| __timestamp | Exelixis, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 12122000 |
| Thursday, January 1, 2015 | 96351000 | 13380000 |
| Friday, January 1, 2016 | 95967000 | 21221000 |
| Sunday, January 1, 2017 | 112171000 | 26887000 |
| Monday, January 1, 2018 | 182257000 | 27863000 |
| Tuesday, January 1, 2019 | 336964000 | 55908000 |
| Wednesday, January 1, 2020 | 547851000 | 59392000 |
| Friday, January 1, 2021 | 693716000 | 69012000 |
| Saturday, January 1, 2022 | 891813000 | 36082000 |
| Sunday, January 1, 2023 | 1044071000 | 24537000 |
| Monday, January 1, 2024 | 910408000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Exelixis, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting trajectories in their R&D investments. Exelixis, Inc. has shown a remarkable growth in R&D expenses, increasing by over 450% from 2014 to 2023. This surge underscores their commitment to pioneering new therapies and maintaining a competitive edge. In contrast, Ligand Pharmaceuticals has maintained a more conservative approach, with R&D expenses peaking in 2021 and then declining by nearly 65% by 2023. This divergence highlights different strategic priorities: while Exelixis focuses on aggressive expansion, Ligand may be optimizing its existing portfolio. As the biotech landscape continues to shift, these trends offer a glimpse into the strategic decisions shaping the future of healthcare innovation.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE